BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 23301733)

  • 1. JAKs and STATs in immunity, immunodeficiency, and cancer.
    O'Shea JJ; Holland SM; Staudt LM
    N Engl J Med; 2013 Jan; 368(2):161-70. PubMed ID: 23301733
    [No Abstract]   [Full Text] [Related]  

  • 2. Inborn errors of human JAKs and STATs.
    Casanova JL; Holland SM; Notarangelo LD
    Immunity; 2012 Apr; 36(4):515-28. PubMed ID: 22520845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK-STAT pathway: impact on human disease and therapeutic intervention.
    O'Shea JJ; Schwartz DM; Villarino AV; Gadina M; McInnes IB; Laurence A
    Annu Rev Med; 2015; 66():311-28. PubMed ID: 25587654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of T cell homeostasis by JAKs and STATs.
    Ross JA; Nagy ZS; Cheng H; Stepkowski SM; Kirken RA
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):231-45. PubMed ID: 17659375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in study on drugs targeting the JAKs/STATs passway].
    Sheng L; Li Y
    Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):162-5. PubMed ID: 16850627
    [No Abstract]   [Full Text] [Related]  

  • 6. Inteferons pen the JAK-STAT pathway.
    Schindler C; Plumlee C
    Semin Cell Dev Biol; 2008 Aug; 19(4):311-8. PubMed ID: 18765289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
    Sansone P; Bromberg J
    J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.
    O'Sullivan LA; Liongue C; Lewis RS; Stephenson SE; Ward AC
    Mol Immunol; 2007 Apr; 44(10):2497-506. PubMed ID: 17208301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
    Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
    Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S; Bar-Natan M; Mascarenhas JO
    Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging roles of JAK-STAT signaling pathways in adipocytes.
    Richard AJ; Stephens JM
    Trends Endocrinol Metab; 2011 Aug; 22(8):325-32. PubMed ID: 21561789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
    Lee K; Evans MG; Yang L; Ng S; Snowden C; Khodadoust M; Brown RA; Trum NA; Querfeld C; Doan LT; Song J; Zhang H; Gru AA; Wood GS; Wada DA; Shanmugam V; Haun PL; Aster JC; Duncan LM; Guitart J; Weinstock DM; Nardi V; Choi J
    Blood; 2021 Dec; 138(23):2435-2440. PubMed ID: 34432866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
    Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
    Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
    Pérez C; González-Rincón J; Onaindia A; Almaráz C; García-Díaz N; Pisonero H; Curiel-Olmo S; Gómez S; Cereceda L; Madureira R; Hospital M; Suárez-Massa D; Rodriguez-Peralto JL; Postigo C; Leon-Castillo A; González-Vela C; Martinez N; Ortiz-Romero P; Sánchez-Beato M; Piris MÁ; Vaqué JP
    Haematologica; 2015 Nov; 100(11):e450-3. PubMed ID: 26294736
    [No Abstract]   [Full Text] [Related]  

  • 17. Basic Science for the clinician 41: tails of cytokine receptor activation and control: JAKs, STATs, PIASs, and SOCSs.
    Sigal LH
    J Clin Rheumatol; 2006 Dec; 12(6):315-9. PubMed ID: 17149068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to Cytokines and Interferons that Depend upon JAKs and STATs.
    Stark GR; Cheon H; Wang Y
    Cold Spring Harb Perspect Biol; 2018 Jan; 10(1):. PubMed ID: 28620095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SnapShot: Jak-STAT Signaling II.
    Villarino AV; Gadina M; O'Shea JJ; Kanno Y
    Cell; 2020 Jun; 181(7):1696-1696.e1. PubMed ID: 32589961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.